Mediantechn (ALMDT) - Total Assets
Based on the latest financial reports, Mediantechn (ALMDT) holds total assets worth €19.43 Million EUR (≈ $22.72 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Mediantechn (ALMDT) net assets for net asset value and shareholders' equity analysis.
Mediantechn - Total Assets Trend (2008–2024)
This chart illustrates how Mediantechn's total assets have evolved over time, based on quarterly financial data.
Mediantechn - Asset Composition Analysis
Current Asset Composition (December 2024)
Mediantechn's total assets of €19.43 Million consist of 84.2% current assets and 15.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 33.4% |
| Accounts Receivable | €9.37 Million | 38.4% |
| Inventory | €48.00K | 0.2% |
| Property, Plant & Equipment | €1.41 Million | 5.8% |
| Intangible Assets | €2.22 Million | 9.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Mediantechn's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALMDT market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mediantechn's current assets represent 84.2% of total assets in 2024, a decrease from 92.7% in 2008.
- Cash Position: Cash and equivalents constituted 33.4% of total assets in 2024, up from 7.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 2.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 38.4% of total assets.
Mediantechn Competitors by Total Assets
Key competitors of Mediantechn based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Mediantechn - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.35 | 0.69 | 1.71 |
| Quick Ratio | 0.35 | 0.69 | 1.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-27.11 Million | €-12.89 Million | €11.29 Million |
Mediantechn - Advanced Valuation Insights
This section examines the relationship between Mediantechn's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 252.66 |
| Latest Market Cap to Assets Ratio | 8.22 |
| Asset Growth Rate (YoY) | -32.2% |
| Total Assets | €24.37 Million |
| Market Capitalization | $200.33 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Mediantechn's assets at a significant premium (8.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Mediantechn's assets decreased by 32.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mediantechn (2008–2024)
The table below shows the annual total assets of Mediantechn from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €24.37 Million ≈ $28.49 Million |
-32.18% |
| 2023-12-31 | €35.94 Million ≈ $42.01 Million |
+3.40% |
| 2022-12-31 | €34.75 Million ≈ $40.63 Million |
-29.63% |
| 2021-12-31 | €49.39 Million ≈ $57.74 Million |
+95.33% |
| 2020-12-31 | €25.28 Million ≈ $29.56 Million |
+56.84% |
| 2019-12-31 | €16.12 Million ≈ $18.85 Million |
-11.17% |
| 2018-12-31 | €18.15 Million ≈ $21.22 Million |
-46.85% |
| 2017-12-31 | €34.14 Million ≈ $39.92 Million |
-26.66% |
| 2016-12-31 | €46.55 Million ≈ $54.43 Million |
+38.76% |
| 2015-12-31 | €33.55 Million ≈ $39.22 Million |
+87.74% |
| 2014-12-31 | €17.87 Million ≈ $20.89 Million |
+4178.62% |
| 2013-12-31 | €417.66K ≈ $488.29K |
-14.49% |
| 2012-12-31 | €488.41K ≈ $571.00K |
-95.34% |
| 2011-12-31 | €10.47 Million ≈ $12.24 Million |
+124.34% |
| 2010-12-31 | €4.67 Million ≈ $5.46 Million |
-7.05% |
| 2009-12-31 | €5.02 Million ≈ $5.87 Million |
-13.80% |
| 2008-12-31 | €5.83 Million ≈ $6.81 Million |
-- |
About Mediantechn
Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnos… Read more